Cumulative Tenofovir Exposure Among Patients With HIV/Hepatitis B Coinfection With Differential Viral Suppression

Helen L Zhang; Meredith Mock; Lane Bushman; Peter L Anderson; Jennifer J Kiser; Susanna Naggie

doi:10.1093/cid/ciae241

Cumulative Tenofovir Exposure Among Patients With HIV/Hepatitis B Coinfection With Differential Viral Suppression

Clin Infect Dis. 2024 Sep 26;79(3):705-708. doi: 10.1093/cid/ciae241.

Authors

Helen L Zhang¹, Meredith Mock², Lane Bushman³, Peter L Anderson³, Jennifer J Kiser³, Susanna Naggie⁴

Affiliations

¹ Hospital Medicine Section, Medicine Specialty Service, Durham VA Medical Center, Durham, North Carolina, USA.
² Department of Physician Assistant Studies, The George Washington University School of Medicine and Health Sciences, Washington D.C., USA.
³ Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado-Anschutz Medical Campus, Aurora, Colorado, USA.
⁴ Division of Infectious Diseases, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.

Abstract

This case-control study explored cumulative tenofovir exposure among patients with human immunodeficiency virus/hepatis B virus (HIV/HBV) coinfection with HIV viral suppression. Among patients taking tenofovir disoproxil fumarate, median TFV-DP levels in dried blood spots were ∼3-fold lower among patients with incomplete HBV viral suppression (n = 4) compared to those with complete suppression (n = 5) (516 vs 1456 fmol/punch).

Keywords: adherence; antiretroviral therapy; dried blood spots; tenofovir-diphosphate; virologic failure.

© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected].

MeSH terms

Adult
Anti-HIV Agents / therapeutic use
Antiviral Agents / therapeutic use
Case-Control Studies
Coinfection* / drug therapy
Coinfection* / virology
Female
HIV Infections* / complications
HIV Infections* / drug therapy
HIV Infections* / virology
Hepatitis B virus / drug effects
Hepatitis B* / complications
Hepatitis B* / drug therapy
Humans
Male
Middle Aged
Tenofovir* / therapeutic use
Viral Load* / drug effects

Substances

Tenofovir
Anti-HIV Agents
Antiviral Agents

Abstract

MeSH terms

Substances

Grants and funding